, Volume 14, Issue 2, pp 71–77 | Cite as

Joint health: What degree of evidence is necessary to support health claims for food supplements, taking glucosamine as an example?

  • Jürgen BernhardtEmail author
  • Christof Jaenicke
  • Peter Prock
  • Ulrich Schneider
Open Access


Arthropathies present a major challenge for the public health system, both in terms of epidemiology and health economics, particularly against the background of demographic changes in the Western world. Much attention must be paid to prevention, because of the limited options and high technical and financial expenditure with respect to treatment. Among other factors, nutrition plays an important role. However, many and various unsolved questions must be answered before health claims for food constituents in the field of joint health can be established for use as consumer information, as will be described taking glucosamine as an example. These questions will be discussed and possible alternatives to conventional practice considered.


glucosamine joint health health claims nutrition degree of evidence 


  1. 1.
    Kaplan W, Laing R (2004) Priority medicines for Europeand the world. World Health Organization Department ofEssential Drugs and Medicines Policy, GenevaGoogle Scholar
  2. 2.
    OECD (2010) Health at a glance: Europe 2010. OECD Publishing. Scholar
  3. 3.
    Arthritis Foundation (2010) A national public health agendafor osteoarthritis 2010. (Accessed December2012)Google Scholar
  4. 4.
    de Vries J, Antoine JM, Burzykowski T, Chiodini A, GibneyM, Kuhnle G, Meheust A, Pijls L, Rowland I (2013) Markersfor nutrition studies: review of criteria for the evaluationof markers. Eur J Nutr 52: 1685–1699Google Scholar
  5. 5.
    Blumberg J, Heaney RP, Huncharek M, Scholl T, StampferM, Vieth R, Weaver CM, Zeisel SH (2010) Evidence-basedcriteria in the nutritional context. Nutr Rev 68: 478–484Google Scholar
  6. 6.
    Setnikar I, Giachetti C, Zanolo G (1984) Absorption, distributionand excretion of radioactivity after a single intravenousor oral administration of [14C] glucosamine to therat. Pharmatherapeutica 3: 538–550Google Scholar
  7. 7.
    Setnikar I, Palumbo R, Canali S, Zanolo G (1993) Pharmacokineticsof glucosamine in man. Arzneimittelforschung43: 1109–1113Google Scholar
  8. 8.
    Setnikar I, Rovati LC (2001) Absorption, distribution, metabolismand excretion of glucosamine sulfate. A review.Arzneimittelforschung 51: 699–725Google Scholar
  9. 9.
    Block JA, Oegema TR, Sandy JD, Plaas A (2010) The effectsof oral glucosamine on joint health: is a change in researchapproach needed? Osteoarthritis Cartilage 18: 5–11CrossRefGoogle Scholar
  10. 10.
    Meulyzer M, Vachon P, Beaudry F, Vinardell T, Richard H,Beauchamp G, Laverty S (2009) Joint inflammation increasesglucosamine levels attained in synovial fluid followingoral administration of glucosamine hydrochloride.Osteoarthritis Cartilage 17: 228–234Google Scholar
  11. 11.
    Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, PaganiniD, Antonioli D, Roda A (2007) Synovial and plasmaglucosamine concentrations in osteoarthritic patients followingoral crystalline glucosamine sulphate at therapeuticdose. Osteoarthritis Cartilage 15: 764–772Google Scholar
  12. 12.
    Derfoul A, Miyoshi AD, Freeman DE, Tuan RS (2007) Glucosaminepromotes chondrogenic phenotype in both chondrocytesand mesenchymal stem cells and inhibits MMP-13expression and matrix degradation. Osteoarthritis Cartilage15: 646–655Google Scholar
  13. 13.
    Naito K, Watari T, Furuhata A, Yomogida S, Sakamoto K,Kurosawa H, Kaneko K, Nagaoka I (2010) Evaluation of theeffect of glucosamine on an experimental rat osteoarthritismodel. Life Sci 86: 538–543Google Scholar
  14. 14.
    Chen D, Zhang Z, Cao J, Zhang D, Jia B (2010) [Effect ofglucosamine hydrochloride capsules on articular cartilageof rabbit knee joint in osteoarthritis]. ZhongguoXiu FuChong JianWaiKeZaZhi 24: 287–291Google Scholar
  15. 15.
    Oegema TR Jr, Deloria LB, Sandy JD, Hart DA (2002) Effectof oral glucosamine on cartilage and meniscus in normaland chymopapain-injected knees of young rabbits. ArthritisRheum 46: 2495–2503CrossRefGoogle Scholar
  16. 16.
    Scarpellini M, Lurati A, Vignati G, Marrazza MG, Telese F,Re K, Bellistri A (2008) Biomarkers, type II collagen, glucosamineand chondroitin sulfate in osteoarthritis followup:the “Magenta osteoarthritis study”. J OrthopTraumatol9: 81–87Google Scholar
  17. 17.
    Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD,Vignon E (2001) Cross sectional evaluation of biochemicalmarkers of bone, cartilage, and synovial tissue metabolismin patients with knee osteoarthritis: relations with diseaseactivity and joint damage. Ann Rheum Dis 60: 619–626Google Scholar
  18. 18.
    Cahue S, Sharma L, Dunlop D, Ionescu M, Song J, LobanokT, King L, Poole AR (2007) The ratio of type II collagen breakdownto synthesis and its relationship with the progressionof knee osteoarthritis. OsteoarthrCartil 15: 819–823Google Scholar
  19. 19.
    Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C, GarneroP (2007) A 5-yr longitudinal study of type IIA collagensynthesis and total type II collagen degradation in patientswith knee osteoarthritis: association with disease progression.Rheumatology (Oxford) 46: 938–943Google Scholar
  20. 20.
    Christgau S, Henrotin Y, Tanko LB, Rovati LC, Collette J,Bruyere O, Deroisy R, Reginster JY (2004) Osteoarthriticpatients with high cartilage turnover show increased responsivenessto the cartilage protecting effects of glucosaminesulphate. ClinExpRheumatol 22: 36–42Google Scholar
  21. 21.
    Yoshimura M, Sakamoto K, Tsuruta A, Yamamoto T, IshidaK, Yamaguchi H, Nagaoka I (2009) Evaluation of the effectof glucosamine administration on biomarkers for cartilageand bone metabolism in soccer players. Int J Mol Med24: 487–494Google Scholar
  22. 22.
    Momomura R, Naito K, Igarashi M, Watari T, Terakado A,Oike S, Sakamoto K, Nagaoka I, Kaneko K (2013) Evaluationof the effect of glucosamine administration on biomarkersof cartilage and bone metabolism in bicycle racers. MolMed Rep 7: 742–746Google Scholar
  23. 23.
    Navarro SL, White E, Kantor ED, Zhang Y, Rho J, Song X,Milne GL, Lampe PD, Lampe JW (2015) Randomized trialof glucosamine and chondroitin supplementation on inflammationand oxidative stress biomarkers and plasmaproteomics profiles in healthy humans. PLoS ONE10: e0117534Google Scholar
  24. 24.
    Largo R, Martinez-Calatrava MJ, Sanchez-Pernaute O, MarcosME, Moreno-Rubio J, Aparicio C, Egido J, Herrero-BeaumontG (2009) Effect of a high dose of glucosamine onsystemic and tissue inflammation in an experimental modelof atherosclerosis aggravated by chronic arthritis. Am JPhysiol Heart CircPhysiol 297: H268–H276Google Scholar
  25. 25.
    Azuma K, Osaki T, Wakuda T, Tsuka T, Imagawa T, OkamotoY, Minami S (2012) Suppressive effects of N-acetyl-D-glucosamineon rheumatoid arthritis mouse models. Inflammation35: 1462–1465Google Scholar
  26. 26.
    Kantor ED, Lampe JW, Navarro SL, Song X, Milne GL, WhiteE (2014) Associations between glucosamine and chondroitinsupplement use and biomarkers of systemic inflammation.J Altern Complement Med 20: 479–485Google Scholar
  27. 27.
    Damlar I, Esen E, Tatli U (2015) Effects of glucosaminechondroitincombination on synovial fluid IL-1beta, IL-6,TNF-alpha and PGE2 levels in internal derangements oftemporomandibular joint. Med Oral Patol Oral Cir Bucal20(3): e278 - 83Google Scholar
  28. 28.
    EFSA Panel on Dietetic Products N.a.A.N. (2012) Scientificopinion on the substantiation of a health claim related toglucosamine and maintenance of normal joint cartilagepursuant to Article 13(5) f Regulation (EC) No 1924/2006.EFSA J 10 (5): 2691Google Scholar
  29. 29.
    EFSA Panel on Dietetic Products, N.a.A.N. (2012) Guidanceon the scientific requirements for health claims related tobone, joints, skin and oral health. EFSA J 10 (5): 2702Google Scholar
  30. 30.
    Pavelka K, Gatterova J, Olejarova M, Machacek S, GiacovelliG, Rovati LC (2002) Glucosamine sulfate use and delay ofprogression of knee osteoarthritis: a 3-year, randomized,placebo-controlled, double-blind study. Arch Intern Med162: 2113–2123Google Scholar
  31. 31.
    Henrotin Y, Chevalier X, Herrero-Beaumont G, McAlindonT, Mobasheri A, Pavelka K, Schon C, Weinans H, BiesalskiH (2013) Physiological effects of oral glucosamine on jointhealth: current status and consensus on future research priorities.BMC Res Notes 6: 115–116. doi:  10.1186/1756-0500-6-115 Google Scholar
  32. 32.
    Runhaar J, van Middelkoop M, Reijman M, Willemsen S,Oei EH, Vroegindeweij D, van Osch G, Koes B, Bierma-ZeinstraSM (2015) Prevention of knee osteoarthritis in overweightfemales; the first preventive randomized controlledtrial in osteoarthritis. Am J Med 10 pii: S0002-9343(15)00244-2. doi: 10.1016/j.amjmed.2015. 03. 006Google Scholar
  33. 33.
    World Cancer Research Fund/American Institute for CancerResearch. 2007. Food, nutrition, physical activity, and theprevention of cancer: a global perspective. AICR, Washington,DCGoogle Scholar
  34. 34.
    Somogyi A, Hathcock J, Biesalski HK, Blumberg JB, AntoineJM, Edwards G, Prock P (2011) Scientific issues related toCodex Alimentarius goals: a review of principles, with examples.RegulToxicolPharmacol 60: 161–164Google Scholar

Copyright information

© The Author(s) 2015

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Jürgen Bernhardt
    • 1
    Email author
  • Christof Jaenicke
    • 2
  • Peter Prock
    • 3
  • Ulrich Schneider
    • 4
  1. 1.BioTeSys GmbHEsslingenGermany
  2. 2.analyze&realize GmbHBerlinGermany
  3. 3.European Nutraceutical AssociationBaselSwitzerland
  4. 4.Osteoarthritis Research CenterTegernseeGermany

Personalised recommendations